SAN DIEGO, April 22 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optmer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.
"Randomized Clinical Trial (RCT) in Clostridium difficile Infection (CDI) Confirms Superiority of Fidaxomicin over Vancomycin" Oral Presentation by: Stuart Johnson, M.D. Tuesday, May 4, 2010 2:15pm-3:45pm Central Daylight Time Abstract number: 828630 Location: Ballroom C, Ernest N. Morial Convention Center
SOURCE Optimer Pharmaceuticals, Inc.